Related Experiment Video
Updated: Jun 8, 2026
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
Clinical Applications of Microbiome in Renal Cell Carcinoma
Sara Elyas1, Pedro Barata2, Ulka Vaishampayan3
1Lyman Briggs College, Michigan State University, East Lansing, MI, USA.
Abstract:
Advancements in microbiome research reveal its impact on cancer treatment outcomes, particularly in renal cell carcinoma (RCC). While immune checkpoint inhibitors (ICIs) have improved survival in metastatic RCC, composition of the gut microbiome has the potential to influence their efficacy. Antibiotic-induced microbiome disruptions correlate with diminished outcomes, while strains such as Akkermansia muciniphila, Clostridium butyricum, and others enhance immune responses and progression-free survival. Some prebiotics such as inulin gel can alter the gut flora to overcome the resistant strains occurring in response to immune therapy. This mini-review explores microbiome-targeted interventions, such as pre/probiotics and fecal microbiota transplantation, for overcoming ICI resistance. Although promising, prospective randomized trials are needed to standardize clinical applications and optimize microbiome-targeted treatments. The standard use of gut-modulating therapy cannot be recommended at present outside of clinical trials. A double-blind placebo-controlled randomized trial of ICI ± gut modulating therapy is being planned in frontline therapy of advanced RCC (BIOFRONT trial by the Southwest Oncology Group).
Insights
The gut microbiome influences cancer treatment outcomes, especially for renal cell carcinoma (RCC) patients receiving immune checkpoint inhibitors (ICIs). Modulating the microbiome with prebiotics or probiotics may improve responses to these therapies.
Area of Science:
- Oncology
- Microbiome Research
- Immunotherapy
Background:
- Immune checkpoint inhibitors (ICIs) have improved survival in metastatic renal cell carcinoma (RCC).
- Gut microbiome composition significantly impacts the efficacy of ICI therapy.
- Disruptions to the microbiome, such as from antibiotics, are linked to poorer treatment outcomes.
Purpose of the Study:
- To explore microbiome-targeted interventions for overcoming resistance to immune checkpoint inhibitors (ICIs) in cancer treatment.
- To review the role of specific microbial strains and prebiotics in enhancing anti-cancer immune responses.
- To discuss the potential of prebiotics, probiotics, and fecal microbiota transplantation in improving ICI efficacy.
Main Methods:
- Review of current literature on microbiome research and its connection to cancer therapy.
- Analysis of studies investigating specific bacterial strains (e.g., Akkermansia muciniphila, Clostridium butyricum) and their effects.
- Exploration of prebiotic interventions like inulin gel for altering gut flora.
Main Results:
- Certain gut microbial strains are associated with enhanced immune responses and improved progression-free survival in patients treated with ICIs.
- Prebiotic interventions show potential in modulating the gut microbiome to overcome resistance to immunotherapy.
- Microbiome-targeted therapies, including pre/probiotics and fecal microbiota transplantation, are promising for enhancing ICI efficacy.
Conclusions:
- Microbiome-targeted interventions hold promise for improving outcomes in advanced RCC patients treated with ICIs.
- Further prospective randomized trials are essential to standardize clinical applications and optimize these treatments.
- Current gut-modulating therapies are not recommended outside of clinical trials, with ongoing studies like the BIOFRONT trial investigating their role.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
06:29Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
